Klinische und biochemische Zielsetzungen bei der Thrombolysetherapie mit Neothrombolytika speziell mit Gewebeplasminogenaktivator, Prourokinase und deren Kombinationen
- 1 September 1988
- journal article
- research article
- Published by Georg Thieme Verlag KG in Hamostaseologie
- Vol. 08 (05) , 199-213
- https://doi.org/10.1055/s-0038-1659926
Abstract
No abstract availableThis publication has 70 references indexed in Scilit:
- Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarctionThe American Journal of Cardiology, 1987
- Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agentsAmerican Heart Journal, 1986
- High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial infarction: Description of effects in the circulationThe American Journal of Cardiology, 1986
- Coronary thrombolysis in dogs with intravenously administered human pro-urokinase.Circulation, 1985
- A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits.Circulation, 1985
- Isolation of a human tissue-type plasminogen-activator genomic DNA clone and its expression in mouse L cellsGene, 1985
- Coronary thrombolysis with recombinant human tissue-type plasminogen activator.Circulation, 1984
- Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology.Circulation, 1984
- Common evolutionary origin of the fibrin‐binding structures of fibronectin and tissue‐type plasminogen activatorFEBS Letters, 1983
- Effects of Intravenous Administration of Fibrinolysin (Plasmin) in ManCirculation, 1959